Insulin-regulated transcription factors: Molecular link between insulin resistance and cardiovascular risk factors

International Journal of Obesity

Volumn 25, Issue , 2001, Pages S35-S37

  Muller Wieland D ^a   Knebel, B ^a   Avci, H ^a   Lehr, S ^a   Laudes, M ^a   Ristow, M ^a   Krone, W ^a   Kotzka, J ^a  

^a UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

Author keywords

ADD 1; Cfos; Lipoatrophy; MAP kinase cascade; SREBP

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; TRANSCRIPTION FACTOR;

ARTICLE; BODY WEIGHT; CARDIOVASCULAR RISK; GENETIC PREDISPOSITION; GENETIC REGULATION; HUMAN; HYPERINSULINEMIA; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPOATROPHY; MOLECULAR GENETICS; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK FACTOR; TRANSCRIPTION REGULATION;

ANIMALS; CARDIOVASCULAR DISEASES; CCAAT-ENHANCER-BINDING PROTEINS; DNA-BINDING PROTEINS; GENE EXPRESSION REGULATION; HUMANS; INSULIN; INSULIN RESISTANCE; LIPID METABOLISM; MAP KINASE SIGNALING SYSTEM; OBESITY; RISK FACTORS; STEROL REGULATORY ELEMENT BINDING PROTEIN 1; TRANSCRIPTION FACTORS;

EID: 0034967187     PISSN: 03070565     EISSN: 14765497     Source Type: Journal    
DOI: 10.1038/sj.ijo.0801694     Document Type: Article

References (23)

1. Haffner SN, Lehto N, Rönnemaa T, Pyörälä K, Laakso M. Mortality from coronary heart disease in subjects with type 2 diabetes and in non-diabetic subjects with and without myocardial infarction. New Engl ¡Med 1998; 339: 229-234.
2. Hobbs HH, Brown MS, Goldstein JL. Molecular genetics of the LDL receptor gene in familial hypercholesterolemia. Hum Mut 1992; 1: 445-466.
3. Soutar AK. Update on low density lipoprotein receptor mutations. Curr Opin Lipidol 1998; 9: 141-147.
4. Barsh GS, Farooqi IS, O'Rahilly S. Genetics of body-weight regulation. Nature 2000; 404: 644-651.
5. Hegele RA. Insulin resistance in human partial lipodystrophy. Curr Atherosclerosis Reports 2000; 2: 397-404.
6. Moitra J, Mason MM, Olive M, Krylov D, Gavrilova O, Marcus-Samuels B, Feigenbaum L, Lee E, Aoyama T, Eckhaus M, Reitman ML, Vinson C. Life without white fat: a transgenic mouse. Genes Dev 1998; 12: 3168-3181.
7. Treisman R. Regulation of transcription by MAP kinase cascades. Curr Opin Cell Biol 1996; 8: 205-215.
8. Widman C, Gibson S, Jarpe MB, Johnson GL. Mitogen-activated protein kinase: conservation of a three-kinase module from yeast to human. Physiol Rev 1999; 79: 143-180.
9. Knebel B, Kellner S, Kotzka J, Siemeister G, Dreyer M, Streicher, M, Schiller M, Rüdiger HW, Seemanova E, Krone W, Müller-Wieland D. Defects of insulin and IGF-1 action at receptor and postreceptor level in a patient with type A syndrome of insulin resistance. Biochem Biophys Res Commun 1997; 234: 626-630.
10. Knebel B, Avci H, Kotzka J, Schiller M, Krone W, Müller-Wieland D. Genetic defect in the cfos promoter impairing insulin action. Diabetes 1999; 48(Suppl 1): A61.
11. Knebel B, Kotzka J, Avci H, Schiller M, Brüning JC, Hafner M, Krone W, Müller-Wieland D. Characterization of a postreceptor signaling defect that impairs cfos expression in cultured fibroblasts of a patient with insulin resistance. Biochem Biophys Res Commun 2000; 268: 577-582.
12. Whitmarsh AJ, Davis RJ. Regulation of transcription factor function by phosphorylation. Cell Life Sei 2000; 57: 1172-1183.
13. Ristow M, Müller-Wieland D, Pfeiffer A, Krone W, Kahn CR. Obesity associated with a mutation in peroxisome-proliferator activated receptor gamma 2 (PPAR-2), a regulator of adipocited differentiation. New Engl f Med 1998; 339: 953-959.
14. Auwerx J, Mangelsdorf D. X-receptors, nuclear receptors for metabolism. In Stemme S, Olsson AG (eds). Atherosclerosis 12, Excerpta Medica, International Congress Series 1215. Elsevier Science B.V.: Amsterdam; 2000. pp 21-39.
15. Kotzka J, Müller-Wieland D, Kopponen A, Njamen D, Kremer L, Munck M, Knebel B, Roth G, Krone W. ADDl/SREBP-lc: transcription factor mediating insulin action via MAP-kinase pathway. Biochem Biophys Res Com 1998; 249: 375-379.
16. Kotzka J, Müller-Wieland D, Roth G, Kremer L, Munck M, Schürmann S, Knebel B, Krone W. Sterol regulatory element binding proteins (SREBP)-la and SREBP-2 are linked to the MAP-kinase cascade. J Lipid Res 2000; 41: 99-108.
17. Roth G, Kotzka J, Kremer L, Lehr S, Lohhaus C, Meyer HE, Krone W, Müller-Wieland D. MAP-kinases Erk-1/2 phosphorylâtes sterol regulatory element-binding protein (SREBP)-la at serin 117 in vitro. J Biol Chem 2000; 275: 33302-33307.
18. Brown MS, Goldstein JL. The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell 1997; 89: 331-340.
19. Brown MS, Goldstein JL. A proteolytic pathway that controls the cholesterol content of membranes, cells, and blood. Proc Natl Acad Sei USA 1999; 96: 11041-11048.
20. Streicher R, Kotzka J, Müller-Wieland D, Siemeister G, Munck M, Avci H, Krone W. SREBP-1 mediates activation of the low density lipoprotein receptor promotor by insulin and insulin-like growth factor-1. /Biol Chem 1996; 271: 7128-7133.
21. Kim JB, Spiegelman BM. ADD1/SREBP-1 promotes adipocyte differentiation in gene expression linked to fatty acid metabolism. Genes Dev 1996; 10: 1096-1107.
22. Shimomura I, Hammer RE, Richardson JA, Ikemoto S, Bashmakov Y, Goldstein JL, Brown MS. Insulin resistance and diabetes mellitus in transgenic mice expressing nuclear SREBP-lc in adipose tissue: model for congenital generalized lipodystrophy. Genes Dev 1998; 12: 3182-3194.
23. Shimomura I, Hammer RE, Ikemoto S, Brown MS, Goldstein JL. Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 1999; 401: 73-76.